10 results
POS AM
LSB
LakeShore Biopharma Co., Ltd
23 Jan 24
Prospectus update (post-effective amendment)
4:18pm
products and businesses and regulates almost all of the key stages of the life-cycle of pharmaceutical products, including nonclinical studies, clinical … process for the assessment, control, communication and review of quality risks, throughout the entire product life cycle.
The NMPA issued
424B3
LSB
LakeShore Biopharma Co., Ltd
15 Aug 23
Prospectus supplement
8:00am
of the key stages of the life-cycle of pharmaceutical products, including nonclinical studies, clinical trials, marketing approvals, manufacturing … for the assessment, control, communication and review of quality risks, throughout the entire product life cycle.
The NMPA issued the amended appendix
POS AM
LSB
LakeShore Biopharma Co., Ltd
8 Aug 23
Prospectus update (post-effective amendment)
4:06pm
all of the key stages of the life-cycle of pharmaceutical products, including nonclinical studies, clinical trials, marketing approvals, manufacturing … for the assessment, control, communication and review of quality risks, throughout the entire product life cycle.
The NMPA issued the amended appendix
20-F
2023 FY
LSB
LakeShore Biopharma Co., Ltd
26 Jul 23
Annual report (foreign)
4:02pm
”). The NMPA is the primary regulatory agency for pharmaceutical products and businesses and regulates almost all of the key stages of the life-cycle … for the assessment, control, communication and review of quality risks, throughout the entire product life cycle.
The NMPA issued the amended appendix
424B3
blh54
5 Jun 23
Prospectus supplement
4:03pm
F-1/A
4al0qay irll6uka69
12 May 23
Registration statement (foreign) (amended)
4:05pm
F-1
8wqosn
12 Apr 23
Registration statement (foreign)
8:49am
F-4
EX-10.10
g14x3a9
28 Dec 22
Registration of securities (foreign)
6:58am
DRS/A
EX-10.10
oyoz ifxzgcy
14 Nov 22
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next